OEP Business Summary

Orient EuroPharma Co., Ltd. (OEP) operates a vertically integrated biopharmaceutical business model, generating revenue through a dual-track strategy focused on specialty pharmaceuticals (approximately 60% of revenue) and nutritional supplements (40%). The company’s primary business segments include Prescription Medicines, which targets therapeutic areas such as cardiology, oncology, and central nervous system disorders; Nutricare, anchored by the globally recognized "Karihome" goat milk brand; and Dermo-cosmetics. OEP further diversifies its income through its subsidiary, Orient Pharma (4166.TWO), which provides contract development and manufacturing (CDMO) services and develops 505(b)(2) new drugs. Within the competitive landscape, OEP competes directly with regional players such as Nang Kuang Pharmaceutical, Synmosa Biopharma, YungShin Global Holding, and Lotus Pharmaceutical, distinguishing itself through its niche dominance in the Asian goat milk market and a robust licensing-in model for international pharmaceutical partnerships. The company was founded in 1982 by Chairman Peter Tsai (Cheng-Yang Tsai), a former executive at Upjohn who established OEP as a prescription drug distributor before evolving it into a multinational group. The current leadership is led by CEO and General Manager Calvin Tsai (Mon-Lin Tsai), the founder’s son and a U.S.-trained CPA with a professional pedigree at Elan Pharmaceuticals and Pierre Fabre. Key management includes Jack Wu, who oversees the high-growth Nutricare business unit, and Cynthia Lin, a long-standing Director representing the company's major shareholder, Taiwan Excelsior Co., Ltd. The 18th Board of Directors, seated through June 2028, maintains a strategic focus on Southeast Asian expansion and U.S. market entry for its CNS and metabolic syndrome pipelines.